SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBAR is trending due to news of FedEx joining its Governing Council and reported US military adoption for quantum-secure drones, leading to a strong division among investors with many highlighting its real-world utility and institutional partnerships, while others express skepticism over its price performance and question its fundamentals.

Codatta

XNY CRYPTO is trending as the community actively discusses its strong performance and resilience during broader market pullbacks, attributing its momentum to its utility in AI and decentralized data.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is actively trending following the FDA approval of Nereus for motion sickness, with community attention now shifting to its blockbuster potential for GLP-1 induced nausea and the highly anticipated Bysanti PDUFA decision in February. Investors are debating the company's undervalued status and the likelihood of a major buyout or partnership driven by these significant pipeline developments, amidst concerns over management's performance and a recent shelf offering.

Polygon

Polygon is trending following its strategic pivot into regulated payments and Real-World Asset (RWA) leadership, bolstered by recent acquisitions and a surge in network usage and stablecoin volume; the community is actively discussing its strong long-term growth prospects despite some frustration over price action.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as investors await critical legal decisions, including a Supreme Court review of its patent infringement case and antitrust rulings, while an FDA clarification on fenofibrates is seen as opening significant market opportunities for Vascepa. The community is also keenly discussing its China market strategy and growing speculation around a potential acquisition, especially following recent positive financial updates.

Block, Inc. engages in creating ecosystems for distinct customer audiences. It operates through the Square and Cash App segments. The Square segment provides payment services, software solutions, hardware, and financial services to sellers. The Cash App segment includes the financial tools available to individuals within the mobile Cash App, including peer-to-peer payments, bitcoin and stock investments. It also includes Cash App Card, which is linked to customer stored balances that customers can use to pay for purchases or withdraw funds from an ATM. The company was founded by Jack Patrick Dorsey and James Morgan McKelvey in February 2009 and is headquartered in Oakland, CA.

Block Inc - Ordinary Shares - Class A

Block Inc

Block (XYZ) is trending after unveiling ambitious profit growth forecasts through 2028 and authorizing a new $5 billion share buyback, igniting hopes among some investors for a significant turnaround and long-term value. However, a frustrated segment of the community remains wary, pointing to the stock's historical underperformance and broader concerns about the fintech sector's future amid ongoing competition and macroeconomic pressures.

Kaspa was fair-launched in November 2021 with no pre-mine, zero pre-sale, and no coin allocations, and is 100 percent community-managed. Kaspa aims to be the world's global sequencer for traditional finance and decentralized crypto markets by utilizing proof-of-work and its BlockDAG consensus protocol, GHOSTDAG. Being the world's fastest proof-of-work network, Kaspa combines five properties: (1) hard money principles, (2) Bitcoin's ethos of security-first fundamentals (boasting a security threshold of fifty percent with significant market hashrate), (3) decentralization from rapid block rate mining, (4) block speeds faster than any PoW or PoS network, and (5) smart contract development through based-rollups without fragmented liquidity. Ushering in all five properties, Kaspa is on track to fulfill Satoshi Nakamoto's vision of a digital medium of exchange while also advancing global layer-one sequencing and minuscule confirmation times dominated by internet latency (cf. chapter 6 of the the paper for some initial benchmarks). The Kaspa implementation includes a lot of cool features and subprotocols including Reachability to query the DAG's topology, Block data pruning (with near-future plans for block header pruning), SPV proofs, and later subnetwork support which will make future implementation of layer 2 solutions much easier.

Kaspa

Kaspa (KAS) is trending for its unique BlockDAG technology, delivering highly scalable and secure Proof-of-Work, with the community actively discussing upcoming smart contract implementations and potential major exchange listings. While many hail KAS as a "sleeping giant" poised for significant growth, others express skepticism over its recent price performance and perceived delays in wider adoption.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

The crypto community is actively discussing $DOG's momentum, driven by its Bitcoin-native, fair-launch ethos and recent reports of trading support rolling out on Coinbase, with many believing it is positioned to outperform rivals like DOGE by dropping the 'E'.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending amid heightened speculation of a sweetened acquisition offer from Sanofi, following its rejected $16/share bid, as investors eagerly await imminent SOL-1 Phase 3 superiority trial data. The community is highly optimistic about potential blockbuster results for its wet AMD treatment, with discussions fueled by a key executive hire with a strong industry track record, pointing towards a significant premium or robust independent commercialization.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is actively trading amidst broad tech sector volatility, with the community sharply divided between those buying dips for potential recovery and those concerned about leveraged ETF decay, against a backdrop of ongoing geopolitical tensions and uncertain Federal Reserve policy. Traders are closely watching key support levels as market sentiment shifts between short-term rebounds and longer-term caution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Achilles Therapeutics Plc is a biopharmaceutical company engaged in developing transformative precision T-cell therapies to treat multiple types of solid tumors. It focuses on researching, developing and commercializing potentially novel cancer immunotherapies targeting clonal neoantigens. The company was founded by Karl Peggs, Sergio Quezada, Mark Lowdell and Charles Swanton in November 2020 and is headquartered in London, the United Kingdom.

Achilles Therapeutics Plc - ADR

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

ACHL
Achilles Therapeutics Plc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ACHL News

ACHLAchilles Therapeutics Plc - ADR